Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. News about CMPX often centers on its antibody pipeline, clinical trial progress, financing activities, and corporate developments, reflecting its focus on angiogenesis, immune modulation, and tumor growth.
Investors and observers following Compass Therapeutics news can expect regular updates on key product candidates such as tovecimig, CTX-8371, CTX-10726, and CTX-471. The company issues press releases on milestones in the COMPANION-002 Phase 2/3 study of tovecimig in advanced biliary tract cancer, monotherapy data in metastatic colorectal cancer, and cohort expansions or new responses in the Phase 1 study of CTX-8371 in indications like non-small cell lung cancer, triple negative breast cancer, and Hodgkin Lymphoma. Preclinical data releases for CTX-10726, including presentations at scientific meetings, also feature prominently.
Compass Therapeutics news coverage additionally includes quarterly financial results, cash and marketable securities updates, and descriptions of anticipated cash runway, as disclosed in earnings press releases and related Form 8-K filings. The company also announces public offerings of common stock and pre-funded warrants, with details on intended use of proceeds for research, clinical development, and preparations for potential commercialization.
Another recurring theme in CMPX news is participation in healthcare and biopharma investor conferences, where Compass presents its pipeline and corporate strategy. Press releases list appearances at events hosted by firms such as J.P. Morgan, Piper Sandler, Evercore, Guggenheim, Stifel, Cantor, and others. Leadership appointments, including additions to the senior management team, are also communicated through Globe Newswire releases.
This news page aggregates these company-issued updates and related coverage, offering a centralized view of clinical, scientific, financial, and corporate developments for Compass Therapeutics and its CMPX stock.
Compass Therapeutics (NASDAQ: CMPX) provided a corporate update on January 6, 2026, reporting pipeline progress, leadership hires, upcoming data readouts, and a cash position. Key items include PFS and OS analyses for tovecimig on track for late Q1 2026, a planned Phase 2 DLL4+ basket study following COMPANION-002 analysis, and a 5% ORR (2/40) for tovecimig monotherapy in heavily pretreated colorectal cancer (all had prior bevacizumab).
For CTX-8371, cohort expansions in TNBC and NSCLC (n=28 each) are open with dose levels 3.0 and 10.0 mg/kg; a third confirmed response in Hodgkin lymphoma was reported. CTX-10726 Phase 1 is expected to start in Q1 2026. Estimated cash and marketable securities were $209 million as of December 31, 2025, providing runway into 2028.
Compass Therapeutics (Nasdaq: CMPX) granted inducement stock options to two newly appointed executives under its 2025 Inducement Plan on January 5, 2026.
The company awarded 1,000,000 non‑qualified stock options to Chief Commercial Officer Arjun Prasad and 1,000,000 to Chief Medical Officer Cynthia Sirard, each with an exercise price of $5.17 (closing price on January 2, 2026). The options carry a 10‑year term and vest over four years (25% after one year, then 36 monthly installments). Grants were approved by the Compensation Committee and made as material inducements under Nasdaq Rule 5635(c)(4).
Compass Therapeutics (Nasdaq: CMPX) announced the appointments of Arjun Prasad, MBA, MPH as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, effective January 1, 2026.
Mr. Prasad joins from Servier Pharmaceuticals and has led >10 oncology launches including the 2024 launch of VORANIGO and commercialization of TIBSOVO for biliary tract cancer. Dr. Sirard joins from Leap Therapeutics with prior leadership at Sanofi and Genzyme, and has guided programs through IND filings, clinical development, pivotal trials, and regulatory approval. Management says these hires strengthen Compass’s ability to advance tovecimig and its oncology pipeline.
Compass Therapeutics (Nasdaq: CMPX) will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026. The presentation is scheduled for 7:30 AM PT and will be webcast at cmpx.info/jpmorgan.
Virtual replay and an archived copy will be available on Compass’ Events page. Compass is also hosting investor meetings as part of the LifeSci Partners Corporate Access Event on January 12–13, 2026 in San Francisco. Investors seeking one-on-one meetings should contact their J.P. Morgan or LifeSci representative to request meetings.
Compass Therapeutics (Nasdaq: CMPX) will participate in two investor events in December 2025: the Piper Sandler 37th Annual Healthcare Conference in New York on Dec 2, 2025 at 8:00 AM ET and the Evercore 8th Annual Healthcare Conference in Coral Gables on Dec 4, 2025 at 10:00 AM ET.
Live webcasts are provided for each presentation and recordings will be archived for 90 days on Compass’ Events page. Management will be available for one-on-one meetings during both events; interested investors should contact their representatives to request meetings.
Compass Therapeutics (NASDAQ:CMPX) reported Q3 2025 results and a clinical update. The company had $220 million in cash and marketable securities as of September 30, 2025, which management expects will provide runway into 2028. Clinical highlights include a met primary endpoint for tovecimig in COMPANION-002 and pooled OS/PFS analyses expected in late Q1 2026 (triggered at 80% pooled OS events). CTX-8371 Phase 1 fully enrolled with no dose-limiting toxicities and cohort expansions for NSCLC and TNBC planned in Q4 2025. CTX-10726 IND filing is planned for Q4 2025 with initial data expected in H2 2026.
Compass Therapeutics (Nasdaq: CMPX) presented preclinical data on CTX-10726, a tetravalent bispecific antibody targeting PD-1 and VEGF-A, at the 40th SITC Annual Meeting on November 7, 2025.
Key findings: CTX-10726 showed high-affinity binding to human and cynomolgus VEGF-A and PD-1, dose-dependent blockade of VEGF-A/VEGFR2 and PD-1/PD-L1 interactions, and potent IFN-γ immunomodulatory activity in vitro. In vivo, CTX-10726 produced tumor elimination in multiple models and demonstrated superior anti-tumor activity versus comparator antibodies including ivonescimab and bevacizumab in xenograft and knock-in mouse models. The company said an IND submission is on track for Q4 2025. Presentation materials will be posted on the company website after the meeting.
Compass Therapeutics (Nasdaq: CMPX) will participate in three investor events in November 2025: Guggenheim Healthcare Innovation Conference in Boston on Nov 10, 2025 at 3:30 PM ET, Stifel 2025 Healthcare Conference in New York on Nov 12, 2025 at 4:00 PM ET, and Jefferies Global Healthcare Conference in London on Nov 20, 2025 at 12:00 PM GMT.
Each presentation will be webcast; links are provided and presentations will be archived for 90 days on Compass’ Events page for replay.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology biopharmaceutical company, has announced its participation in four major investor conferences in September 2025:
- Citi's Biopharma Back to School Conference in Boston (Sept 2)
- Cantor Global Healthcare Conference in New York (Sept 3, 2:10 PM ET)
- H.C. Wainwright Global Investment Conference in New York (Sept 8, 11 AM ET)
- Morgan Stanley Global Healthcare Conference in New York (Sept 9, 5:35 PM ET)
All presentations will be archived for 90 days on Compass' Events page.
Compass Therapeutics (NASDAQ: CMPX), a clinical-stage oncology biopharmaceutical company, has announced the pricing of an upsized public offering totaling $120 million. The offering consists of 33,290,000 shares of common stock priced at $3.00 per share and pre-funded warrants to purchase 6,710,000 shares at $2.9999 per warrant.
The underwriters have a 30-day option to purchase up to 6 million additional shares. The offering is expected to close around August 14, 2025. The company plans to use the proceeds for commercial readiness preparations, research and clinical development of product candidates, and general corporate purposes.